The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

People taking the drugs had a lower risk of organ failure and death However, the drugs were associated with an increased risk of diabetic retinopathy THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 ...

THURSDAY, March 6, 2025 (HealthDay News) -- GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients ...

This tool enables users to create presentations and edit slides using Generative AI in Google Slides. The AI-powered suggestions are a game-changer. It's like having a personal presentation assistant.

For patients with diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) don’t appear to increase suicidality over what’s seen with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or ...

Participants Patients with type 2 diabetes. Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 ...

“Yes, I am on a GLP-1, or a weight loss medication." "Now, if you have been following me for a long time, you’ll know that I’ve gained and lost weight several times very publicly," they ...

I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue ...